The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy pill (semaglutide tablets) as the first daily oral GLP-1 treatment for adults with obesity or overweight with weight-related conditions. Based on the OASIS 4 trial, the pill showed about 14% weight loss over 64 weeks compared to 2% with placebo, alongside diet and exercise. This approval offers a non-injectable alternative to weekly semaglutide injections, expanding treatment options for the estimated 15 million people living with obesity in the UK. Novo Nordisk plans to make the pill available via private prescription within weeks, marking the UK as the first European country to approve this treatment.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
